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The purpose of the study is 
to analyze the effect of 
levodopa-metabolizing 
bacteria at it’s primary site 
of absorption, the jejunum, 
and further use this 
information to understand 
the variability in L-DOPA 
dosage requirements for 
individual treatment of Parkinson’s Disease.  
Purpose
Parkinson’s disease is the second most common 
neurodegenerative disorder, which is primarily treated by 
levodopa (L-DOPA)1.  Previous research has shown that 
the microbiota-inhabiting human gut has a significant 
impact on the health of the host and indicate that 
microbiota have a crucial effect on many health and 
diseased states2.  Additionally, studies show that gut 
microbiota can impact the efficacy of drug 
pharmacokinetics and drug bioavailability3, 4.  Previous 
research supports investigation of mechanisms impacting 
L-DOPA treatments in Parkinson’s disease because L-
DOPA varies in efficacy of relieving symptoms among 
Parkinson’s patients5.  Still to be determined is whether 
inter-individual variations in gut microbiota composition 
play a causative role in the variation of L-DOPA treatment 
efficacy. 
Tyrosine decarboxylase genes (tdc) are encoded in the 
genome of several bacterial species in the genera 
Lactobacillus and Enterococcus6.   Tdc might have the 
ability to decarboxylate L-DOPA to produce dopamine7, 
interfering with its bioavailability for therapeutic use.
It was determined that the bacteria 
of the upper small intestinal 
converts levodopa to dopamine.  
A higher relative abundance of 
bacterial Tyrosine decarboxylase 
genes (tdc) in stool samples of 
Parkinson’s Disease patients 
positively correlated with higher 
daily levodopa/carbidopa dosage 
requirement and duration of disease.
The authors conclude that levodopa conversion by bacterial tdc in 
the small intestine should be considered as a significant 
explanatory factor for the increased levodopa/carbidopa dosage 
regimen in a subset of Parkinson’s patients. Therefore, bacteria or 
their encoded tdc gene may serve as a predictive biomarker to 
stratify Parkinson’s patients for efficacy of levodopa treatment.
To investigate whether natural 
variation of tyrosine decarboxylase 
relative abundance in the gut could 
interfere with L-DOPA uptake and 
decarboxylation, human fecal 
samples from Parkinson’s patients on 
varying doses of L-DOPA/carbidopa, 
and jejunal content samples from 
rats on oral L-DOPA/carbidopa 
administration, were employed and 
tyrosine decarboxylase levels were 
detected. All data were ranked from 
low to high by tyrosine 
decarboxylase level and linear 
regression was performed with 
automatic outlier detection using the 
ROUT method in Graphpad Prism 7. 
Statistical tests performed were 
unpaired T-tests, 2-way-ANOVA 
followed by a Fisher’s LSD test.
Results
All p-values in the study were ≤ 0.05, indicating that the strength 
of the evidence is high.  The r-coefficient for the tdc abundance 
and jejunal dopamine levels indicated the strongest positive 
correlation, while tdc abundance and jejunal levodopa/carbidopa 
levels or plasma levodopa/carbidopa levels both demonstrated 
fairly strong negative correlations:
• tdc abundance and jejunal dopamine levels 
• r = 0.78, P value 0.0001
• tdc abundance and jejunal levodopa/carbidopa levels
• r = -0.68, P value 0.021
• tdc abundance and plasma levodopa/carbidopa levels
• r = -0.57, P value 0.017
Human Fecal 
Sample
• n = 10
• Parkinson’s patients on variable 
doses of levodopa/carbidopa 
treatment
Rat Jejunal 
Content
• n = 25
• Wild-type Groningen rats
• treated with E. faecalis v583 cells 
followed by levodopa/carbidopa 
mixture
Analysis
• Quantitative PCR of tdc genes 
performed on DNA extracted 
from each human fecal sample & 
rat jejunal content samples
